FMP
NRx Pharmaceuticals, Inc.
NRXPW
NASDAQ
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
0.067 USD
-0.0067 (-10%)
About
ceo
Dr. Jonathan C. Javitt M.D., M.P.H.
sector
Healthcare
industry
Biotechnology
website
https://www.nrxpharma.comexchange
NASDAQ
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
CIK
0001719406
ISIN
US6294441182
CUSIP
629444118
Address
1201 Orange Street
Phone
484 254 6134
Country
US
Employee
N/A
IPO Date
Dec 1, 2017
Key Executives
